Roberts M Scot 4

4 · Altimmune, Inc. · Filed Feb 3, 2026

AI-generated summary of this filing

Updated Feb 3, 2026

Altimmune (ALT) CSO Roberts M Scot Exercises RSUs, Buys ESPP Shares

What Happened

Roberts M. Scot, Chief Scientific Officer of Altimmune (ALT), had RSUs vest/convert into common stock and participated in the company's ESPP. On 2026-01-30 and 2026-02-02 he converted RSUs totaling 17,050 shares into common stock (9,275 + 7,775), of which 5,188 shares (2,859 + 2,329) were surrendered to cover taxes (received values $16,010 and $12,926). Net from vesting = +11,862 shares. Separately, on 2026-01-31 he purchased 5,567 shares under the ESPP at $3.07 per share for a reported total of $17,091.
These transactions appear to be routine vesting/tax-withholding and an employee purchase (buy), not an open-market sale.

Key Details

Transaction dates and entries:
- 2026-01-30: Conversion/exercise (code M) of 9,275 RSUs -> 9,275 shares acquired; 2,859 shares surrendered for taxes (code F) at $5.60 = $16,010.
- 2026-01-31: ESPP purchase (code A) of 5,567 shares at $3.07 = $17,091 (ESPP period Aug 1, 2025–Jan 31, 2026; purchase price = 85% of Aug 1, 2025 close).
- 2026-02-02: Conversion/exercise (code M) of 7,775 RSUs -> 7,775 shares acquired; 2,329 shares surrendered for taxes (code F) at $5.55 = $12,926.
Net effect from RSU vesting: +11,862 shares (17,050 vested − 5,188 withheld). Total cash value of tax-withheld shares: $28,936.
Shares owned after the transactions: not specified in the provided filing details.
Footnotes of note:
- F1/F5/F6: These are RSUs that vest in substantially equal installments over four years from specified grant dates and have no expiration.
- F2: Shares were surrendered solely to cover taxes associated with RSU vesting.
- F3/F4: ESPP purchase at 85% of the Aug 1, 2025 closing price for the Aug 1, 2025–Jan 31, 2026 offering period.
Filing: Form filed 2026-02-03 covering transactions through 2026-02-02 — appears timely (not marked late).

Context

The RSU conversions were effectively net-share settlements: RSUs vested, converted to shares, and a portion was surrendered to the company to satisfy tax withholding (common, routine). This is not an open-market sale.
The ESPP purchase is an actual buy (employee purchase at a discount), which can be interpreted as a modest insider purchase signal but is part of regular employee benefit participation.
Transaction codes: M = exercise/conversion of derivative (here, RSU vesting/conversion); F = shares surrendered for tax withholding; A = award/grant (ESPP purchase).

Form 4

Period: 2026-01-30

Chief Scientific Officer

Transactions

Exercise/Conversion
Common Stock, par value $0.0001
[F1]
2026-01-30+9,275→ 104,670 total
Tax Payment
Common Stock, par value $0.0001
[F2]
2026-01-30$5.60/sh−2,859$16,010→ 101,811 total
Award
Common Stock, par value $0.0001
[F3][F4]
2026-01-31$3.07/sh+5,567$17,091→ 107,378 total
Exercise/Conversion
Common Stock, par value $0.0001
[F1]
2026-02-02+7,775→ 115,153 total
Tax Payment
Common Stock, par value $0.0001
[F2]
2026-02-02$5.55/sh−2,329$12,926→ 112,824 total
Exercise/Conversion
Restricted Stock Units
[F1][F5]
2026-01-30−9,275→ 9,275 total
→ Common Stock, par value $0.0001 (9,275 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F6]
2026-02-02−7,775→ 0 total
→ Common Stock, par value $0.0001 (7,775 underlying)

Footnotes (6)

[F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
[F2]Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
[F3]These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026.
[F4]In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025.
[F5]The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
[F6]The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Signature

/s/ Gregory Weaver, as Attorney-in-Fact|2026-02-03

1 file